Iron III Hydroxide Polymaltose Complex

Iron III Hydroxide Polymaltose Complex

Exhibitor Products
Iron III Hydroxide Polymaltose Complex
Iron III Hydroxide Polymaltose Complex

Information

Iron (III) Hydroxide Polymaltose Complex (IPC) is a stable, non-ionic iron–carbohydrate complex developed for the treatment and prevention of iron deficiency. Unlike conventional iron salts, iron is present in a polynuclear ferric hydroxide core, stabilized by a polymaltose shell, ensuring controlled iron availability and improved tolerability. This structure allows iron to be released gradually and in a regulated manner, minimizing free iron exposure and significantly reducing gastrointestinal irritation. Due to its stability, IPC shows a low risk of toxicity and is well tolerated, making it suitable for long-term use. Key Features: • Patent held by WBCIL on Iron (III) Hydroxide Polymaltose Complex • Controlled iron release with reduced GI side effects • Non-ionic and highly stable iron complex • Improved patient compliance compared to inorganic iron salts • Supported by COPP and Written Confirmation (WC) Applications: • Iron Deficiency Anemia • Pediatric and Geriatric Supplementation • Pregnancy and Lactation • Long-term Oral Iron Therapy
West Bengal Chemical Industries Ltd.617West Bengal Chemical Industries Ltd (WBCIL) • Established in 1962, WBCIL is a prominent manufacturer of Active Pharmaceutical Ingredients (APIs) and fine chemicals with 62 years of expertise. • Specializes in pharmaceutical, nutraceutical, food, and animal nutrition products. • Operates WHO-GMP-certified manufacturing units in Dahej (Gujarat) and Kolkata. • Recognition & Achievements • Successfully awarded 15 patents for innovative contribution • Honoured with the National Intellectual Property (IP) Award 2024 on March 26, 2025, by the Ministry of Commerce & Industry, Government of India. • Recognized for outstanding patent filing and successful commercialization as an MSME. • Product Portfolio • Premium Mineral Salts: Offers a complete range of mineral salts of iron, calcium, magnesium, and other essential minerals for pharmaceutical and nutraceutical applications. • Liposomal APIs: Specializes in liposomal technology, improving bioavailability and efficacy of APIs for nutraceutical and cosmeceutical uses, including: o Liposomal Vitamins o Liposomal Minerals o Liposomal Herbal o Liposomal Amino Acids • Pellets & DC Granules: Manufactures high-quality customised pellets and DC granules for all listed categories. Eskag Pharma Eskag Pharma, a WBCIL Group company, operates a state-of-the-art WHO-GMP accredited manufacturing facility, specializing in end-to-end contract manufacturing for pharmaceuticals, liposomal nutraceuticals and cosmeceuticals including skin serum, cream and lotion. Its diverse portfolio includes Women and reproductive Healthcare, Hematinic injectables, Iso-osmotic laxatives, anti-ulcerants, Immunity boosters, Liposomal skincare and oral supplements range, and CKD therapies The company offers customized packaging solutions and multilingual artworks (AW) to support global partners across the emerging markets. Neutral code availability and private labelling options enable our business collaborators to launch products efficiently while maintaining brand flexibility and faster market entry. Eskag Pharma maintains a strong and experienced regulatory cell with hands-on expertise in dossier preparation, submission support and efficient query handling for registration submissions. From innovation to impact, WBCIL sets the global standard in API and fine chemical manufacturing, empowering industries and inspiring trust worldwide. "WBCIL isn't just part of the global API and fine chemical industry — we lead it, shaping tomorrow with innovation, trust, and world-class excellence."

Log in

See all the content and easy-to-use features by logging in or registering!